Have a feature idea you'd love to see implemented?
Let us know!
DVAX Dynavax Technologies Corp
Price (delayed)
$12.36
Market cap
$1.62B
P/E Ratio
82.4
Dividend/share
N/A
EPS
$0.15
Enterprise value
$1.76B
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of
Highlights
DVAX's gross margin is up by 24% YoY
Dynavax Technologies's equity has increased by 13% YoY and by 6% from the previous quarter
DVAX's EPS has plunged by 69% YoY but it is up by 15% from the previous quarter
The net income has dropped by 66% year-on-year but it is up by 19% since the previous quarter
DVAX's quick ratio is down by 15% YoY and by 7% QoQ
Key stats
What are the main financial stats of DVAX
Market
Valuations
Earnings
Shares outstanding
131.45M
Market cap
$1.62B
Enterprise value
$1.76B
Price to book (P/B)
2.38
Price to sales (P/S)
6.21
EV/EBIT
56.62
EV/EBITDA
45.08
EV/Sales
6.73
Revenue
$260.81M
EBIT
$31.01M
EBITDA
$38.95M
Free cash flow
$22.67M
Per share
Balance sheet
Liquidity
EPS
$0.15
Free cash flow per share
$0.17
Book value per share
$5.2
Revenue per share
$1.99
TBVPS
$8.08
Total assets
$1.06B
Total liabilities
$380.56M
Debt
$250.17M
Equity
$681.43M
Working capital
$856.21M
Debt to equity
0.37
Current ratio
13.23
Quick ratio
11.98
Net debt/EBITDA
3.36
Margins
Efficiency
Dividend
EBITDA margin
14.9%
Gross margin
82.9%
Net margin
7.9%
Operating margin
-4.2%
Return on assets
2%
Return on equity
3.2%
Return on invested capital
2.9%
Return on capital employed
3.1%
Return on sales
11.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DVAX stock price
How has the Dynavax Technologies stock price performed over time
Intraday
1.56%
1 week
-7.69%
1 month
12.57%
1 year
-8.78%
YTD
-11.59%
QTD
10.95%
Financial performance
How have Dynavax Technologies's revenue and profit performed over time
Revenue
$260.81M
Gross profit
$216.09M
Operating income
-$10.98M
Net income
$20.48M
Gross margin
82.9%
Net margin
7.9%
The company's operating margin has shrunk by 144% YoY but it rose by 34% QoQ
DVAX's operating income has dropped by 132% year-on-year but it is up by 31% since the previous quarter
The net income has dropped by 66% year-on-year but it is up by 19% since the previous quarter
Dynavax Technologies's net margin has plunged by 53% YoY but it has increased by 14% from the previous quarter
Growth
What is Dynavax Technologies's growth rate over time
Valuation
What is Dynavax Technologies stock price valuation
P/E
82.4
P/B
2.38
P/S
6.21
EV/EBIT
56.62
EV/EBITDA
45.08
EV/Sales
6.73
DVAX's EPS has plunged by 69% YoY but it is up by 15% from the previous quarter
DVAX's P/B is 77% below its 5-year quarterly average of 10.5 and 4.8% below its last 4 quarters average of 2.5
Dynavax Technologies's equity has increased by 13% YoY and by 6% from the previous quarter
DVAX's revenue is down by 28% year-on-year but it is up by 4.5% since the previous quarter
The P/S is 11% less than the 5-year quarterly average of 7.0 and 4.5% less than the last 4 quarters average of 6.5
Efficiency
How efficient is Dynavax Technologies business performance
The ROE has plunged by 70% YoY but it has grown by 14% from the previous quarter
Dynavax Technologies's ROA has plunged by 68% YoY but it has increased by 18% from the previous quarter
Dynavax Technologies's return on invested capital has shrunk by 61% YoY but it has increased by 21% QoQ
DVAX's ROS is down by 38% YoY but it is up by 18% from the previous quarter
Dividends
What is DVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DVAX.
Financial health
How did Dynavax Technologies financials performed over time
Dynavax Technologies's total assets is 179% higher than its total liabilities
DVAX's quick ratio is down by 15% YoY and by 7% QoQ
Dynavax Technologies's current ratio has decreased by 14% YoY and by 7% QoQ
Dynavax Technologies's debt is 63% less than its equity
Dynavax Technologies's equity has increased by 13% YoY and by 6% from the previous quarter
The debt to equity has contracted by 12% YoY and by 5% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.